Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing

NCT04213326 ·Status: COMPLETED

Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer

NCT00582387 ·Status: COMPLETED

The Registry Study of Genetic Alterations of Melanoma in Taiwan

NCT06952400 ·Status: RECRUITING

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

NCT04354064 ·Status: RECRUITING

Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy

NCT00897481 ·Status: UNKNOWN

Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

NCT05379907 ·Status: WITHDRAWN

Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease

NCT02612350 ·Status: COMPLETED

Genomic Analysis of Families With a History of Discordant Cancers

NCT04860453 ·Status: RECRUITING

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

NCT05212779 ·Status: ACTIVE_NOT_RECRUITING

The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.

NCT06765850 ·Status: RECRUITING

Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom

NCT00757614 ·Status: UNKNOWN

Melanoma Detection by Oblique-Incidence Optical Spectroscopy

NCT00526032 ·Status: COMPLETED

DNA Repair and Genetic Susceptibility to Lung Cancer

NCT00611598 ·Status: COMPLETED

Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

NCT02790944 ·Status: COMPLETED

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881 ·Status: RECRUITING

Differential Risks for Melanoma: p16 and DNA Repair

NCT00615095 ·Status: COMPLETED

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT05343013 ·Status: RECRUITING ·Phase: PHASE2

Analysis of Molecular Biomarkers in Periocular Adnexal Tumours

NCT06080009 ·Status: RECRUITING ·Phase: NA

Use of Ctdna in Patients With Gastrointestinal Tract Tumors

NCT06202131 ·Status: RECRUITING

Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"

NCT03071809 ·Status: TERMINATED

Understanding the Transition from Normal Melanocytes to Nevus to Melanoma

NCT06605417 ·Status: RECRUITING

Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma

NCT02251314 ·Status: COMPLETED

Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

NCT00899132 ·Status: TERMINATED

Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

NCT04883827 ·Status: COMPLETED

Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

NCT00450593 ·Status: UNKNOWN